Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
351
Nu Skin
NUS
$232M
| $67.9M | 0.06% |
1,776,400
+760,100
| +75% | +$24.4M |
2017 Q4
10 quarters
|
|
|
ELME
352
Elme Communities
ELME
$156M
| $67.8M | 0.06% |
3,055,200
-376,800
| -11% | -$8.39M |
2015 Q3
19 quarters
|
|
353
Idexx Laboratories
IDXX
$40.4B
| $67.1M | 0.06% |
203,180
-147,945
| -42% | -$42.8M |
2013 Q2
28 quarters
|
|
354
Intercontinental Exchange
ICE
$87.2B
| $67M | 0.06% |
731,390
+553,690
| +312% | +$50.7M |
2018 Q4
6 quarters
|
|
|
CZR
355
DELISTED
Caesars Entertainment Corporation
CZR
| $66.7M | 0.06% |
5,498,058
-940,200
| -15% | -$9.5M |
2019 Q2
4 quarters
|
|
356
Thomson Reuters
TRI
$44B
| $66.4M | 0.06% |
928,440
+800,499
| +626% | +$57.9M |
2019 Q4
2 quarters
|
|
357
Union Pacific
UNP
$165B
| $66.3M | 0.06% |
392,074
+273,174
| +230% | +$43.8M |
2020 Q1
1 quarter
|
|
358
Angi Inc
ANGI
$255M
| $66.3M | 0.06% |
545,280
-18,600
| -3% | -$1.7M |
2018 Q3
7 quarters
|
|
|
GTY
359
Getty Realty Corp
GTY
$1.73B
| $65.3M | 0.06% |
2,199,312
-294,700
| -12% | -$7.81M |
2014 Q2
24 quarters
|
|
360
Televisa
TV
$1.18B
| $64.8M | 0.06% |
12,370,158
-1,252,900
| -9% | -$6.94M |
2018 Q1
9 quarters
|
|
361
UBS Group
UBS
$144B
| $64M | 0.06% |
5,541,700
-3,876,700
| -41% | -$39.9M |
2016 Q4
14 quarters
|
|
362
CRH
CRH
$54.5B
| $63.7M | 0.06% |
1,857,100
-304,300
| -14% | -$9.39M |
2016 Q4
14 quarters
|
|
|
CBPO
363
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $63.7M | 0.06% |
623,141
+371,745
| +148% | +$39.8M |
2013 Q2
28 quarters
|
|
364
Malibu Boats
MBUU
$433M
| $63.5M | 0.05% |
1,221,901
-184,992
| -13% | -$7.39M |
2015 Q2
20 quarters
|
|
365
Nomad Foods
NOMD
$1.54B
| $63.4M | 0.05% |
2,957,107
+2,305,207
| +354% | +$48.1M |
2020 Q1
1 quarter
|
|
366
Evertec
EVTC
$1.75B
| $63M | 0.05% |
2,242,587
-117,039
| -5% | -$3.1M |
2014 Q2
24 quarters
|
|
367
Independence Realty Trust
IRT
$3.45B
| $62.7M | 0.05% |
5,459,216
-946,505
| -15% | -$9.44M |
2016 Q1
17 quarters
|
|
368
Rambus
RMBS
$11.8B
| $62.3M | 0.05% |
4,101,086
-326,600
| -7% | -$4.6M |
2013 Q2
28 quarters
|
|
369
EverQuote
EVER
$731M
| $62.2M | 0.05% |
1,070,023
+81,090
| +8% | +$3.81M |
2019 Q2
4 quarters
|
|
370
Cal-Maine
CALM
$3.03B
| $62.2M | 0.05% |
1,398,007
+401,108
| +40% | +$17.1M |
2018 Q1
9 quarters
|
|
371
Coca-Cola Europacific Partners
CCEP
$45.6B
| $61.7M | 0.05% |
1,632,896
+1,294,522
| +383% | +$50.8M |
2014 Q2
24 quarters
|
|
372
America Movil
AMX
$66.1B
| $61.4M | 0.05% |
4,840,449
+1,138,658
| +31% | +$14.2M |
2017 Q3
11 quarters
|
|
373
Edwards Lifesciences
EW
$48.6B
| $61.2M | 0.05% |
885,400
-328,700
| -27% | -$23.4M |
2019 Q4
2 quarters
|
|
374
Viavi Solutions
VIAV
$10.8B
| $60.9M | 0.05% |
4,779,588
-1,537,600
| -24% | -$18.4M |
2015 Q2
20 quarters
|
|
375
Builders FirstSource
BLDR
$5.79B
| $60.5M | 0.05% |
2,923,519
-1,432,000
| -33% | -$25.9M |
2018 Q3
7 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 584 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.